Xilio Therapeutics Inc (XLO) Stock Price, Quote & News

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX...

Industry: Biotechnology

Sector: Healthcare

Phone: 857-524-2466

Website: xiliotx.com

Address:

828 Winter Street, Suite 300, Waltham, United States

deerix Jul. 7 at 7:25 PM

$XLO a move higher is right around the corner

1 · Reply

M1LL5 Jul. 7 at 4:57 PM

$XLO sustaining 👀

0 · Reply

DayTraderBatman Jul. 4 at 10:32 PM

$OGEN With the offering out of the way this might take a bit to move. I am not sure yet how this works and appreciate info. $XLO completed an offering and then has sat at 70 cents for a 2 week period. Not saying they are similar but something to note about the time it could take for it to move.

1 · Reply

LetsCHere Jul. 4 at 10:25 PM

$XLO I had been flipping this unknown diamond for many swing trades over the last few months but you better believe that there is a major uptrend coming for this stock!!!

0 · Reply

Trading_GM Jul. 3 at 2:59 PM

$XLO What is the next catalyst and when?

1 · Reply

Logan12071 Jul. 2 at 7:20 PM

$XLO unless they drop news this is going nowhere

2 · Reply

lookigotmeadollar Jul. 1 at 12:37 AM

$XLO do you think they’ll do more dilution? i mean with their current standings i believe they report cash runway until q1 of 2026

2 · Reply

LabPsycho Jun. 30 at 9:27 PM

$XLO @MoneyPennyStocks Have you been reading my posts and concerns the past year? The management of this company revealed they cared nothing about existing shareholders when they did the massive dilution priced at a fraction of the current share price over a year ago with the GILD deal. And then again recently on so-so news on a few very early stage data points. And lets not forget the push for (if it has not happened already?) increased authorized shares from an existing massive 200 million up to a cataplexy inducing 600 million. What more clues does one need? Existing investors do not matter to them.

0 · Reply

MoneyPennyStocks Jun. 30 at 6:27 PM

$XLO Remember when we took 2 months to climb this back to 1 dollar for compliance and the ceo bitch tanked us after great news with an offering. Now look at her move! So much interest! I sure hope she remains CEO what brilliant business acumen.

0 · Reply

8_seconds Jun. 30 at 1:49 PM

$XLO this is one stale stock, damn. Everyday, absolutely nothing. People dreaming of buyout & making serious profit are just that, dreaming. I was a dumb ass for believing it would happen also.

2 · Reply

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:30 PM EDT - 27 days ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Jun 5, 2025, 6:38 PM EDT - 4 weeks ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Jun 2, 2025, 8:46 AM EDT - 5 weeks ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Jun 2, 2025, 6:11 AM EDT - 5 weeks ago

Xilio Therapeutics Announces Proposed Public Offering

May 31, 2025, 8:00 AM EDT - 5 weeks ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 8, 2025, 7:30 AM EDT - 2 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 4:30 PM EDT - 2 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2025, 4:30 PM EDT - 2 months ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Apr 4, 2025, 4:30 PM EDT - 3 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 11, 2025, 7:30 AM EDT - 4 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:30 PM EST - 4 months ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 10:44 AM EST - 5 months ago

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Feb 12, 2025, 7:35 AM EST - 5 months ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:33 AM EST - 5 months ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Jan 21, 2025, 5:05 PM EST - 5 months ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 17, 2025, 4:30 PM EST - 6 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2024, 7:30 AM EST - 7 months ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 16, 2024, 7:30 AM EST - 7 months ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Nov 7, 2024, 9:15 AM EST - 8 months ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:05 AM EST - 8 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 9:01 AM EDT - 8 months ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 9 months ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Aug 28, 2024, 4:01 PM EDT - 11 months ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:30 AM EDT - 11 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

May 14, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Apr 1, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Mar 28, 2024, 7:05 AM EDT - 1 year ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Feb 28, 2024, 4:01 PM EST - 1 year ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Jan 31, 2024, 4:01 PM EST - 1 year ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 8, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Dec 7, 2023, 7:30 AM EST - 1 year ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Nov 9, 2023, 4:01 PM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Oct 31, 2023, 9:15 AM EDT - 1 year ago

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

Sep 27, 2023, 5:02 PM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 5, 2023, 8:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.

Sep 5, 2023, 7:30 AM EDT - 1 year ago

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Aug 14, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

May 25, 2023, 5:01 PM EDT - 2 years ago

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Mar 2, 2023, 4:05 PM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at Upcoming Investor Conferences

Feb 16, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

Feb 2, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

Nov 23, 2022, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

Nov 9, 2022, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

deerix Jul. 7 at 7:25 PM

$XLO a move higher is right around the corner

1 · Reply

M1LL5 Jul. 7 at 4:57 PM

$XLO sustaining 👀

0 · Reply

DayTraderBatman Jul. 4 at 10:32 PM

1 · Reply

LetsCHere Jul. 4 at 10:25 PM

$XLO I had been flipping this unknown diamond for many swing trades over the last few months but you better believe that there is a major uptrend coming for this stock!!!

0 · Reply

Trading_GM Jul. 3 at 2:59 PM

$XLO What is the next catalyst and when?

1 · Reply

Logan12071 Jul. 2 at 7:20 PM

$XLO unless they drop news this is going nowhere

2 · Reply

lookigotmeadollar Jul. 1 at 12:37 AM

$XLO do you think they’ll do more dilution? i mean with their current standings i believe they report cash runway until q1 of 2026

2 · Reply

LabPsycho Jun. 30 at 9:27 PM

0 · Reply

MoneyPennyStocks Jun. 30 at 6:27 PM

0 · Reply

8_seconds Jun. 30 at 1:49 PM

$XLO this is one stale stock, damn. Everyday, absolutely nothing. People dreaming of buyout & making serious profit are just that, dreaming. I was a dumb ass for believing it would happen also.

2 · Reply

levystrauss Jun. 27 at 2:32 PM

$XLO Ok I asked Chatgpt and I finally understood that there are no new shares but pre-funded warrants and if the price remains below 0.75 no one will exercise so as of today Xilio has cashed in the money but there are still no new shares.

0 · Reply

JIM237 Jun. 27 at 10:21 AM

$XLO adding shares weekly while at this level

0 · Reply

levystrauss Jun. 26 at 3:16 PM

$XLO

0 · Reply

Logan12071 Jun. 26 at 3:09 PM

$XLO 1800 watchers and a dead chat

2 · Reply

Meowtard Jun. 26 at 1:52 AM

$XLO next to rip like $CTMX

0 · Reply

biohuntress Jun. 25 at 4:25 PM

$XLO 2025 upcoming catalysts and milestones.....seeking XTX 101 Vilastobart partnership by mid-year 2025.........Gilead XTX 301 development milestone $17.5M ( prior to potential Phase 1/2 opt-in for $75M) ......nominate development candidate for PSMA Q3 2025........Nominate development candidate for CLDN18.2 Q4 2025 ( both may trigger Abbvie milestone payments)

0 · Reply

M1LL5 Jun. 25 at 3:48 PM

$XLO patience aye

0 · Reply

lookigotmeadollar Jun. 25 at 2:53 AM

$CTMX $XLO i had to take my CTMX profits, i’ve loaded them all into XLO, this is bigger than CTMX🤫

1 · Reply

chris306 Jun. 23 at 9:08 PM

$XLO

0 · Reply

MoneyPennyStocks Jun. 22 at 6:14 AM

$XLO Day time frame. C test .75 to .89 range with some push back. Once we hit the gap of .96 we will begin a move to 1.40.

2 · Reply

Twills08 Jun. 20 at 9:20 PM

It’s been an interesting week. Iran and the Fed obviously dominating the landscape: Oil stocks and gold reaping the rewards. Predicting the market‘s moves is like marrying a narcissistic, bipolar with borderline traits. Since some of us have had that experience, follow for more. We can see the map to profit before you do. We trade better as a team. $ATCH $ATPC $ITRM $MIST $XLO

2 · Reply

LabPsycho Jun. 20 at 9:16 PM

$XLO @smolcapcat Great reply. From memory, I was not thinking / expecting any update til later this year, and as you point out completion of early clinicals ~ 2 yr away. I hope you make out great with this investment. I am likely going to wait unless some eye popping surprise announcement with there clinical trials. It possible they get another 180 day extension / no reverse split for a while. A lot can happen over the next year. Good luck

0 · Reply

Market Cap	36.14M
Revenue (ttm)	6.34M
Net Income (ttm)	-58.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-918.61%
Debt to Equity Ratio	0.00

Volume	357,700
Avg Vol	1,539,230
Day's Range	N/A - N/A
Shares Out	51.78M
Stochastic %K	91%
Beta	-0.15
Analysts	Strong Sell
Price Target	$4.00